Insider Transactions in Q1 2025 at Arrowhead Pharmaceuticals, Inc. (ARWR)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 07
2025
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,550
+0.25%
|
$191,000
$20.1 P/Share
|
|
Feb 06
2025
|
Douglas S Ingram Director |
BUY
Grant, award, or other acquisition
|
Direct |
38,396
+50.0%
|
$767,920
$20.09 P/Share
|
|
Jan 23
2025
|
Adeoye Y Olukotun Director |
SELL
Open market or private sale
|
Direct |
959
-2.61%
|
$20,139
$21.0 P/Share
|
|
Jan 07
2025
|
Kenneth Allen Myszkowski Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
18,000
-1.92%
|
$342,000
$19.7 P/Share
|
|
Jan 07
2025
|
Patrick O'Brien COO and General Counsel |
SELL
Open market or private sale
|
Direct |
8,000
-1.49%
|
$152,000
$19.69 P/Share
|
|
Jan 06
2025
|
Kenneth Allen Myszkowski Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
27,167
-2.75%
|
$516,173
$19.89 P/Share
|
|
Jan 06
2025
|
Patrick O'Brien COO and General Counsel |
SELL
Open market or private sale
|
Direct |
29,184
-2.62%
|
$554,496
$19.9 P/Share
|
|
Jan 06
2025
|
James C Hamilton Chief Discovery/Trans Medicine |
SELL
Open market or private sale
|
Direct |
32,729
-5.51%
|
$621,851
$19.9 P/Share
|
|
Jan 04
2025
|
Kenneth Allen Myszkowski Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+16.65%
|
-
|
|
Jan 04
2025
|
Patrick O'Brien COO and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+15.05%
|
-
|
|
Jan 04
2025
|
James C Hamilton Chief Discovery/Trans Medicine |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+24.7%
|
-
|
|
Jan 02
2025
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,520
-0.31%
|
$218,880
$19.05 P/Share
|